about
Evaluation of an Enzyme Immunoassay for Detection of Dengue Virus NS1 Antigen in Human SerumEvaluation of Two New Commercial Tests for the Diagnosis of Acute Dengue Virus Infection Using NS1 Antigen Detection in Human SerumPooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programmePost-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization.Heritability of the human infectious reservoir of malaria parasitesAllelic diversity of the Plasmodium falciparum erythrocyte membrane protein 1 entails variant-specific red cell surface epitopes.Use of HRP-2-based rapid diagnostic test for Plasmodium falciparum malaria: assessing accuracy and cost-effectiveness in the villages of Dielmo and Ndiop, Senegal.Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Clinical and virological study of dengue cases and the members of their households: the multinational DENFRAME Project.Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.Risk factors associated with asthma, atopic dermatitis and rhinoconjunctivitis in a rural Senegalese cohort.Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.An in vivo and in vitro model of Plasmodium falciparum rosetting and autoagglutination mediated by varO, a group A var gene encoding a frequent serotype.Asthma and atopic dermatitis are associated with increased risk of clinical Plasmodium falciparum malaria.Whole-cell pertussis vaccine induces low antibody levels in human immunodeficiency virus-infected children living in sub-Saharan Africa.Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies.Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view.From current vaccine recommendations to everyday practices: An analysis in five sub-Saharan African countries.Viral etiology of respiratory infections in children under 5 years old living in tropical rural areas of Senegal: The EVIRA project.Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults.Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease.Risk factors for Toxoplasma infection in pregnancy: a case-control study in France.An In Vivo and In Vitro Model of Plasmodium falciparum Rosetting and Autoagglutination Mediated by varO, a Group A var Gene Encoding a Frequent Serotype.Correction: Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study.Pain caused by measles, mumps, and rubella vaccines: A systematic literature review.Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy.Plague: Bridging gaps towards better disease controlReply to Lee et al.'s letter to the editor pertaining to our publication entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review"The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling studyIntroducing new vaccines in low- and middle-income countries: challenges and approachesHealthcare utilization, provisioning of post-exposure prophylaxis, and estimation of human rabies burden in MadagascarPersistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patientsAcute rhabdomyolysis during treatment with ofloxacin-a case report
P50
Q27477683-D79AE7F7-1061-4A06-BA15-169724A05C8EQ27486601-80427C56-CA07-4273-8917-7C7826A0E67BQ30780649-131C7E17-6325-4652-B878-FA6C068CA5FCQ33163984-615528E9-E26C-498B-BED1-0804BBD6A56AQ33267285-D650AA72-6A42-4E04-94DE-E3CB116DABD5Q33308717-5B87AA6E-8FB3-43C2-9D0E-312DCE7D8755Q33627561-75F4C37D-B04A-43D2-AAE7-E9C6ED3885C1Q33813188-5FF032BB-762B-4168-8A03-2DF4AC9C09CFQ33922076-C4824A4F-344B-4B68-933D-BC75E97ECEE9Q33953881-148CE535-F3F2-45E4-86A0-C5A50AAF1C0CQ34146653-5CCA54B9-349D-4732-AD15-D8C9A6C1B19EQ34610151-4513DFC8-95AE-4AE5-AC58-8F237FFD5782Q35048280-0907E4AA-D741-47D7-84B0-9CBD29A69454Q35990357-D662194E-E9E0-47C6-B4A2-10C333FC338FQ36675963-30AA5D79-0846-492B-B303-D1F0A8589564Q36974515-93F9C90D-46BC-4425-B661-33202B272D02Q37065057-F5CF89F3-1F7B-4820-9267-4584BDDB97BBQ37156766-DCC6D20D-CCCA-4548-99CB-D4B516463D4BQ37473234-FD270D16-92D0-4D17-860C-3821DD5F5250Q37505531-008ACCAF-A66E-474C-B3AB-A9B24FD3232AQ38248947-02CCAC44-DC02-4D23-9100-01E52909FF9DQ38808226-FDE9AE29-D625-4921-81D4-D856BB9AED6EQ38969591-F83FE6B8-1446-4CF6-AE2D-560BA2DF0BD8Q39303040-209E48B8-EDFA-447A-B413-CA87879AB9EDQ40162193-DC98643F-04F1-4C3E-BBC7-19EA5DAFCF79Q41553104-E7B64A48-6D09-47BE-864D-CF9178CB4AFDQ44002546-A5DA004C-62A1-448B-8D71-F5623EC15950Q45050784-3F5AA49E-E1F9-4746-B45D-D519B8AEED3EQ45100230-A4228579-5D25-4BBA-9C25-FBB4505AB600Q46117266-4F8F376D-68B6-417D-B890-23EB2FFFB382Q49392029-432A6012-9C86-4ADD-9C47-F9724E5B82F6Q50147684-F4A65975-507E-4638-8AE4-054F2290E66BQ52021394-D95614E1-11A1-44DB-9A76-56EE8AFEAA91Q56559985-5C31A6B0-4E69-44FB-990E-86A044218C85Q57789356-A32B2001-AE40-4383-B53A-2C4B3870AD41Q60191965-C26BE582-5600-4F7D-9E6B-E75D0DF76788Q62487400-BFDD6CA8-6CE4-4C5F-8691-CB9DB6145130Q62488348-9E2A83D3-1BDE-4227-A780-4CC24FF86BE9Q72013851-856C055B-086F-4BE8-AEEB-261326FC2383Q73240163-E3EC54F3-24E8-412E-BECC-0F67B81D3E23
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laurence Baril
@ast
Laurence Baril
@en
Laurence Baril
@es
Laurence Baril
@nl
Laurence Baril
@sl
type
label
Laurence Baril
@ast
Laurence Baril
@en
Laurence Baril
@es
Laurence Baril
@nl
Laurence Baril
@sl
prefLabel
Laurence Baril
@ast
Laurence Baril
@en
Laurence Baril
@es
Laurence Baril
@nl
Laurence Baril
@sl
P108
P106
P108
P31
P496
0000-0003-2346-883X